Amgen's Imdelltra plus AstraZeneca's Imfinzi cuts death risk by 58% in small cell lung cancer Phase 3 trial
Amgen reported results from a Phase 3 trial evaluating its investigational therapy Imdelltra in combination with AstraZeneca’s immunotherapy Imfinzi in patients with small cell lung cancer.
The study, conducted in the first‑line maintenance setting, showed that adding Imdelltra reduced the risk of death by 58% compared with Imfinzi alone.
The magnitude of benefit exceeds the pre‑specified benchmark for overall survival, suggesting the combination could become a new standard for this patient population.
The data were presented at the European Society for Medical Oncology (ESMO) meeting in Madrid.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “#ESMO26: Amgen's Imdelltra regimen more than halves risk of death in Phase 3 lung cancer trial”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that